

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

DIACRIN INC /DE/  
Form SC 13D/A  
April 22, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
OMB APPROVAL  
-----

OMB Number: 3235-0145  
Expires: December 31, 2005  
Estimated average burden  
hours per response.....11

SCHEDULE 13D

Under the Securities and Exchange Act of 1934

(Amendment No. 3) \*

DIACRIN, INC.

-----  
(Name of Issuer)

Common Stock, \$.01 par value per share

-----  
(Title of Class of Securities)

25243N103

-----  
(CUSIP Number)

Jeffrey B. Steinberg  
HealthCare Ventures LLC  
44 Nassau Street  
Princeton, New Jersey 08542  
(609) 430-3900

-----  
(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

April 14, 2003

-----  
(Date of Event which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box .

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

-----  
\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 25243N103

13D

Page 2 of 17 Pages

---

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

HealthCare Ventures II, L.P.

---

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)

(b)

---

3 SEC USE ONLY

---

4 SOURCE OF FUNDS\*

WC

---

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

---

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

---

7 SOLE VOTING POWER

NUMBER OF  
SHARES

---

8 SHARED VOTING POWER

BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,196,385

---

9 SOLE DISPOSITIVE POWER

---

10 SHARED DISPOSITIVE POWER

WITH

3,196,385

---

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,196,385

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

17.82%

14 TYPE OF REPORTING PERSON\*

PN

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No.25243N103

13D

Page 3 of 17 Pages

1 NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

HealthCare Partners II, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)

(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS\*

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

7 SOLE VOTING POWER

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

NUMBER OF  
SHARES

---

8 SHARED VOTING POWER

BENEFICIALLY OWNED BY

3,196,385

---

EACH

9 SOLE DISPOSITIVE POWER

REPORTING PERSON

---

10 SHARED DISPOSITIVE POWER

WITH

3,196,385

---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,196,385

---

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

---

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

17.82%

---

14 TYPE OF REPORTING PERSON\*

PN

---

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 25243N103

13D

Page 4 of 17 Pages

---

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

HealthCare Ventures III, L.P.

---

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)

(b)

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

---

3 SEC USE ONLY

---

4 SOURCE OF FUNDS\*

WC

---

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

---

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

---

7 SOLE VOTING POWER

NUMBER OF  
SHARES  
BENEFICIALLY

---

8 SHARED VOTING POWER

994,078

OWNED BY

---

EACH 9 SOLE DISPOSITIVE POWER

REPORTING

PERSON

---

10 SHARED DISPOSITIVE POWER

WITH

994,078

---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

994,078

---

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

---

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.54%

---

14 TYPE OF REPORTING PERSON\*

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

PN

---

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 25243N103

13D

Page 5 of 17 Pages

---

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

HealthCare Partners III, L.P.

---

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)

(b)

---

3 SEC USE ONLY

---

4 SOURCE OF FUNDS\*

WC

---

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

---

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

---

7 SOLE VOTING POWER

NUMBER OF

SHARES

---

8 SHARED VOTING POWER  
BENEFICIALLY

OWNED BY 994,078

---

EACH 9 SOLE DISPOSITIVE POWER

REPORTING

PERSON

---

10 SHARED DISPOSITIVE POWER

WITH

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

994,078

---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

994,078

---

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

---

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.54%

---

14 TYPE OF REPORTING PERSON\*

PN

---

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 25243N103

13D

Page 6 of 17 Pages

---

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

HealthCare Ventures IV, L.P.

---

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)

(b)

---

3 SEC USE ONLY

---

4 SOURCE OF FUNDS\*

WC

---

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

---

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

---

7	SOLE VOTING POWER
---	-------------------

NUMBER OF  
SHARES

---

8	SHARED VOTING POWER
---	---------------------

BENEFICIALLY  
OWNED BY

291,922

---

9	SOLE DISPOSITIVE POWER
---	------------------------

EACH  
REPORTING  
PERSON

---

10	SHARED DISPOSITIVE POWER
----	--------------------------

WITH

291,922

---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

291,922

---

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

---

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.63%

---

14 TYPE OF REPORTING PERSON\*

PN

---

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 25243N103

13D

Page 7 of 17 Pages

---

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

HealthCare Partners IV, L.P.



Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

---

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a)   
(b)

---

3 SEC USE ONLY

---

4 SOURCE OF FUNDS\*  
WC

---

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

---

6 CITIZENSHIP OR PLACE OF ORGANIZATION  
Delaware

---

7 SOLE VOTING POWER  
NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH  
8 SHARED VOTING POWER  
291,922  
9 SOLE DISPOSITIVE POWER  
10 SHARED DISPOSITIVE POWER  
291,922

---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
291,922

---

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

---

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
1.63%

---

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

14 TYPE OF REPORTING PERSON\*

PN

---

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 25243N103

13D

Page 8 of 17 Pages

---

1 NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

James H. Cavanaugh, Ph.D.

---

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)

(b)

---

3 SEC USE ONLY

---

4 SOURCE OF FUNDS\*

OO

---

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

---

6 CITIZENSHIP OR PLACE OF ORGANIZATION

USA

---

7 SOLE VOTING POWER

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

---

8 SHARED VOTING POWER

4,482,385

---

9 SOLE DISPOSITIVE POWER

---

10 SHARED DISPOSITIVE POWER

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

4,482,385

---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,482,385

---

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

---

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

24.99%

---

14 TYPE OF REPORTING PERSON\*

IN

---

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 25243N103

13D

Page 9 of 17 Pages

---

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Harold R. Werner

---

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)

(b)

---

3 SEC USE ONLY

---

4 SOURCE OF FUNDS\*

OO

---

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) OR 2(e)

---

6 CITIZENSHIP OR PLACE OF ORGANIZATION

USA

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

---

7	SOLE VOTING POWER
---	-------------------

NUMBER OF  
SHARES

---

8	SHARED VOTING POWER
---	---------------------

BENEFICIALLY  
OWNED BY

4,482,385

---

9	SOLE DISPOSITIVE POWER
---	------------------------

EACH

REPORTING  
PERSON

---

10	SHARED DISPOSITIVE POWER
----	--------------------------

WITH

4,482,385

---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,482,385

---

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

---

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

24.99%

---

14 TYPE OF REPORTING PERSON\*

IN

---

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 25243N103

13D

Page 10 of 17 Pages

---

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

William Crouse

---

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a)   
(b)

---

3 SEC USE ONLY

---

4 SOURCE OF FUNDS\*

OO

---

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2 (d) OR 2 (e)

---

6 CITIZENSHIP OR PLACE OF ORGANIZATION

USA

---

7 SOLE VOTING POWER

NUMBER OF

SHARES

---

BENEFICIALLY 8 SHARED VOTING POWER

OWNED BY 4,482,385

---

EACH 9 SOLE DISPOSITIVE POWER

REPORTING

PERSON

---

10 SHARED DISPOSITIVE POWER

WITH

4,482,385

---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,482,385

---

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

---

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

24.99%

---

14 TYPE OF REPORTING PERSON\*

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

IN

---

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 25243N103

13D

Page 11 of 17 Pages

---

1 NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

John W. Littlechild

---

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)

(b)

---

3 SEC USE ONLY

---

4 SOURCE OF FUNDS\*

OO

---

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2 (d) OR 2 (e)

---

6 CITIZENSHIP OR PLACE OF ORGANIZATION

USA

---

7 SOLE VOTING POWER

NUMBER OF 36,000

SHARES

BENEFICIALLY

---

8 SHARED VOTING POWER

OWNED BY 4,482,385

EACH

---

9 SOLE DISPOSITIVE POWER

REPORTING 36,000

PERSON

---

10 SHARED DISPOSITIVE POWER

WITH

4,482,385

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,518,385

---

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

---

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

25.19%

---

14 TYPE OF REPORTING PERSON\*

IN

---

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 25243N103

13D

Page 12 of 17 Pages

---

Item 1. Security and Issuer.

This statement relates to the common stock, \$.01 par value each ("Common Stock") of Diacrin, Inc. (the "Issuer"). The address of the Issuer's principal executive office is Building 96, 13th Street, Charlestown, MA 02120.

---

Item 2. Identity and Background.

(a) The name of the reporting persons are HealthCare Ventures II, L.P. ("HCVII"), HealthCare Partners II, L.P. ("HCPII"), HealthCare Ventures III, L.P. ("HCVIII"), HealthCare Partners III, L.P. ("HCPIII"), HealthCare Ventures IV, L.P. ("HCVIV"), HealthCare Partners IV, L.P. ("HCPIV"), Dr. Cavanaugh and Messrs. Werner, Crouse, and Littlechild (HCVII, HCPII, HCVIII, HCPIII, HCVIV, HCPIV, Dr. Cavanaugh and Messrs. Werner, Crouse and Littlechild are hereafter sometimes hereinafter referred to as the "Reporting Persons"). A copy of their agreement in writing to file this statement on behalf of each of them is attached hereto as Exhibit A(1) HCVII, HCPII, HCVIII and HCPIII, HCVIV and HCPIV are limited partnerships organized and existing under the laws of the State of Delaware. HCPII is the General Partner of HCVII, HCPIII is the General Partner of HCVIII and HCPIV is the General Partner of HCVIV. Dr. Cavanaugh and Messrs. Werner, Crouse and Littlechild are the general partners of HCPII, HCPIII and HCPIV.

(b) The business address for HCVII, HCPII, HCVIII, HCPIII, HCVIV and HCPIV, Dr. Cavanaugh and, Messrs. Werner and Crouse is 44 Nassau Street, Princeton, New Jersey 08542. The business address for Mr. Littlechild is One Kendall Square,

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

Building 300, Cambridge, Massachusetts 02339.

(c) Each of Dr. Cavanaugh and Messrs. Werner, Crouse and Littlechild are general partners of various venture capital investment funds. The address for Dr. Cavanaugh and Messrs. Werner and Crouse is 44 Nassau Street, Princeton, New Jersey 08542 and the address for Mr. Littlechild is One Kendall square, Building 300, Cambridge, MA 02339.

(d) Not Applicable.

-----  
(1) Dr. Cavanaugh and Messrs Werner, Littlechild and Crouse are the general partners of HCPII, HCPIII and HCPIV, the General Partners of HCVII, HCVIII and HCVIV, the record holders of the Issuer's securities.

CUSIP No. 25243N103

13D

Page 13 of 17 Pages

(e) Not Applicable.

(f) Dr. Cavanaugh and Messrs. Werner, Crouse and Littlechild are each individuals who are citizens of the United States.

---

Item 3. Source and Amount of Funds or Other Consideration.

Not Applicable

---

Item 4. Purpose of Transaction.

- (a) Not Applicable.
- (b) Not Applicable.
- (c) Not Applicable.
- (d) Not Applicable.
- (e) Not Applicable.
- (f) Not Applicable.
- (g) Not Applicable.
- (h) Not Applicable.
- (i) Not Applicable.
- (j) Not Applicable.

---

Item 5. Interest in Securities of the Issuer.

(a) HCVII directly beneficially owns 3,196,385 shares of the Common Stock of the Issuer representing 17.82% of the issued and outstanding shares of Common Stock of the Issuer. HCVIII directly beneficially owns 994,078 shares of the Common Stock of the Issuer representing 5.54% of the issued and outstanding shares of Common Stock of the Issuer. HCVIV directly beneficially owns 291,922 shares of the Common Stock of the Issuer representing 1.63% of the issued and outstanding shares of Common Stock of the Issuer. HCPII may be deemed to



Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

indirectly beneficially own 3,196,385 shares of the Common Stock of the Issuer representing 17.82% of the issued and outstanding shares of the Common Stock of the Issuer as the General Partner of HCVII, the registered owner of the shares of Common Stock. HCP III may be deemed to indirectly beneficially own 994,078 shares of the Common Stock of the Issuer representing 5.54% of the issued and outstanding shares of the Common Stock of the Issuer as the General Partner of HCVIII, the registered owner of the shares of Common Stock. HCP IV may be deemed to indirectly beneficially own 291,922 shares of the Common Stock of the Issuer representing 1.63% of the issued and outstanding shares of the Common Stock of the Issuer as the General Partner of HCVIV, the registered owner of the

CUSIP No. 25243N103

13D

Page 14 of 17 Pages

shares of Common Stock. Dr. Cavanaugh and Messrs. Werner, Crouse and Littlechild may be deemed to indirectly beneficially own 4,482,385 shares of the Common Stock of the Issuer representing 24.99% of the issued and outstanding shares of the Common Stock of the Issuer as general partners of each of HCP II, HCP III and HCP IV, the General Partners of HCVII, HCVIII and HCVIV, respectively. In addition, Mr. Littlechild beneficially owns immediately exercisable options to purchase 36,000 shares of the Common Stock of the Issuer.

(b) HCVII and HCP II have the sole power to vote all of the 3,196,385 shares of the Common Stock of the Issuer currently owned by them. HCVIII and HCP III have the sole power to vote all of the 994,078 shares of the Common Stock of the Issuer currently owned by them. HCVIV and HCP IV have the sole power to vote all of the 291,922 shares of the Common Stock of the Issuer currently owned by them. Dr. Cavanaugh and Messrs. Werner, Littlechild and Crouse share the power to vote or direct the vote of the 4,482,385 shares owned by HCVII, HCVIII and HCVIV. In addition, Mr. Littlechild has the sole power to vote or direct the vote of the 36,000 shares beneficially owned by him.

(c) Not Applicable.

(d) Not Applicable.

(e) Not Applicable.

---

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

The Issuer and GenVec, Inc. ("GenVec") jointly announced that they have entered into an Agreement and Plan of Reorganization dated as of April 14, 2003 (the "Reorganization Agreement"), providing for the merger of the Issuer into GenVec (the "Merger"). In the merger, each share of the Issuer's common stock will be exchanged for 1.5292 shares of GenVec's common stock in a tax-free transaction. Upon satisfaction of the conditions precedent contained in the Reorganization Agreement and consummation of the merger contemplated thereby, the Issuer will cease to have independent existence as a reporting person under the Securities and Exchange Act of 1934 and the Reporting Persons will no longer own any shares of Common Stock in the Issuer. In connection with the foregoing, (i) HCVII has agreed to vote 2,886,635 of the Shares owned by it, (ii) HCVIII has agreed to vote 897,757 of the Shares owned by it, and (iii) HCVIV has agreed to vote 263,677 of the Shares owned by it in favor of the proposed reorganization and Merger. HCVII, HCVIII and HCVIV have also agreed not to transfer or otherwise dispose of any of the shares of Common Stock of the Issuer owned by them prior to the proposed reorganization and Merger. A copy of each of the voting agreements summarized herein are attached hereto as Exhibits B, C and

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

D, respectively, and are hereby incorporated by reference.

CUSIP No. 25243N103

13D

Page 15 of 17 Pages

A copy of the Reorganization Agreement has been filed by GenVec as Exhibit 2 to its Form 8-K, filed as of April 14, 2003. Reference is hereby made to such Exhibit.

Except in connection with the proposed reorganization and Merger as described or referred to above, there are no other contracts, arrangements, understandings or relationships among the Reporting Persons, and such persons or any other person with respect to any securities of the Issuer, including but not limited to transfer or voting of any securities of the Issuer, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

---

Item 7. Material to be Filed as Exhibits.

Exhibit A - Joint Filing Agreement.

Exhibit B - Letter Agreement dated April 14, 2003 by and between HCVII and GenVec.

Exhibit C - Letter Agreement dated April 14, 2003 by and between HCVIII and GenVec.

Exhibit D - Letter Agreement dated April 14, 2003 by and between HCVIV and GenVec.

---

CUSIP No. 25243N103

13D  
SIGNATURE

Page 16 of 17 Pages

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 22, 2003  
Princeton, New Jersey

HealthCare Ventures II, L.P.,  
by its General Partner, HealthCare Partners II, L.P.

By: S/Jeffrey Steinberg, Administrative Partner  
-----  
Administrative Partner

Dated: April 22, 2003  
Princeton, New Jersey

HealthCare Partners II, L.P.

By: S/Jeffrey Steinberg, Administrative Partner  
-----  
Administrative Partner

Dated: April 22, 2003

HealthCare Ventures III, L.P.,

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

Princeton, New Jersey

by its General Partner, HealthCare Partners III, L.P.

By: S/Jeffrey Steinberg, Administrative Partner

-----  
Administrative Partner

Dated: April 22, 2003

Princeton, New Jersey

HealthCare Partners III, L.P.

By: S/Jeffrey Steinberg, Administrative Partner

-----  
Administrative Partner

Dated: April 22, 2003

Princeton, New Jersey

HealthCare Ventures IV, L.P.,

by its General Partner, HealthCare Partners IV, L.P.

By: S/Jeffrey Steinberg, Administrative Partner

-----  
Administrative Partner

Dated: April 22, 2003

Princeton, New Jersey

HealthCare Partners IV, L.P.

By: S/Jeffrey Steinberg, Administrative Partner

-----  
Administrative Partner

CUSIP No. 25243N103

13D

Page 17 of 17 Pages

Dated: April 22, 2003

Princeton, New Jersey

By: S/Jeffrey Steinberg, Attorney-in-Fact

-----  
James H. Cavanaugh, Ph.D

Dated: April 22, 2003

Princeton, New Jersey

By: S/Jeffrey Steinberg, Attorney-in-Fact

-----  
Harold R. Werner

Dated: April 22, 2003

Princeton, New Jersey

By: S/Jeffrey Steinberg, Attorney-in-Fact

-----  
William Crouse

Dated: April 22, 2003

Cambridge, Massachusetts

By: S/Jeffrey Steinberg, Attorney-in-Fact

-----  
John W. Littlechild

EXHIBIT A

AGREEMENT

JOINT FILING OF SCHEDULE 13D

The undersigned hereby consent to the joint filing by any of them of a Statement on Schedule 13D and any amendments thereto, whether heretofore or hereafter filed, relating to the securities of Diacrin, Inc., and affirm that this Schedule 13D is being filed on behalf of each of the undersigned.

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

Dated: April 22, 2003  
Princeton, New Jersey

HealthCare Ventures II, L.P.,  
by its General Partner, HealthCare Partners II, L.P.

By: S/Jeffrey Steinberg, Administrative Partner  
-----  
Administrative Partner

Dated: April 22, 2003  
Princeton, New Jersey

HealthCare Partners II, L.P.

By: S/Jeffrey Steinberg, Administrative Partner  
-----  
Administrative Partner

Dated: April 22, 2003  
Princeton, New Jersey

HealthCare Ventures III, L.P.,  
by its General Partner, HealthCare Partners III, L.P.

By: S/Jeffrey Steinberg, Administrative Partner  
-----  
Administrative Partner

Dated: April 22, 2003  
Princeton, New Jersey

HealthCare Partners III, L.P.

By: S/Jeffrey Steinberg, Administrative Partner  
-----  
Administrative Partner

Dated: April 22, 2003  
Princeton, New Jersey

HealthCare Ventures IV, L.P.,  
by its General Partner, HealthCare Partners IV, L.P.

By: S/Jeffrey Steinberg, Administrative Partner  
-----  
Administrative Partner

A-1

Dated: April 22, 2003  
Princeton, New Jersey

HealthCare Partners IV, L.P.

By: S/Jeffrey Steinberg, Administrative Partner  
-----  
Administrative Partner

Dated: April 22, 2003  
Princeton, New Jersey

By: S/Jeffrey Steinberg, Attorney-in-Fact  
-----

James H. Cavanaugh, Ph.D.

Dated: April 22, 2003  
Princeton, New Jersey

By: S/Jeffrey Steinberg, Attorney-in-Fact  
-----

Harold R. Werner

Dated: April 22, 2003  
Princeton, New Jersey

By: S/Jeffrey Steinberg, Attorney-in-Fact  
-----

William Crouse

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

Dated: April 22, 2003  
Cambridge, Massachusetts

By: S/Jeffrey Steinberg, Attorney-in-Fact

-----  
John W. Littlechild

Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

A-2

EXHIBIT B

April 14, 2003

GenVec, Inc.  
65 West Watkins Mill Road  
Gaithersburg, Maryland 20878

Ladies and Gentlemen:

The undersigned is the beneficial holder of shares of Diacrin, Inc. ("Diacrin") common stock, par value \$0.01 per share ("Diacrin Common Stock").

GenVec, Inc. ("GenVec") and Diacrin are considering the execution of an Agreement and Plan of Reorganization (the "Reorganization Agreement") providing for the merger of Diacrin with and into GenVec (the "Merger"). The execution of the Reorganization Agreement is subject, in the case of GenVec, to the execution and delivery of this letter agreement (this "Agreement"). In consideration of the substantial expenses that GenVec will incur in connection with the Merger and in order to induce GenVec to execute the Reorganization Agreement and to proceed to incur such expenses, the undersigned agrees and undertakes, in his capacity as a stockholder of Diacrin, as follows:

1. The undersigned will vote or cause to be voted for approval of the transactions contemplated by the Reorganization Agreement 2,886,635 of the shares of Diacrin Common Stock (the "Subject Shares") the undersigned is entitled to vote with respect thereto, subject, in the case of shares held in a fiduciary capacity, to the fiduciary, contractual or similar obligations of the undersigned.

2. The undersigned will not effect any transfer or other disposition (except by operation of law) of any of the Subject Shares until Diacrin's stockholders have voted to approve the transactions contemplated by the Reorganization Agreement or until the Reorganization Agreement has been terminated pursuant to its terms, except for any transfer mandated by law or court order. In the case of any transfer by operation of law or otherwise, this Agreement shall be binding upon and inure to the benefit of the transferee to the extent permitted by law. Any transfer or other disposition in violation of the terms of this paragraph 2 shall be null and void.

3. During the period beginning on the Effective Date and continuing to and including the date that is 120 days after the Effective Date, the undersigned will not, directly or indirectly (i) offer, sell, contract to sell or otherwise dispose of, any shares of GenVec Common Stock or securities convertible into or exercisable or exchangeable for shares of GenVec common stock or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part, the economic consequences of ownership of shares

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

of GenVec Common Stock whether any such swap or other agreement is to be settled by delivery of shares of GenVec Common Stock, other securities, cash or otherwise.

B-1

April 14, 2003

Page 2

4. The undersigned acknowledges and agrees that any remedy at law for breach of the foregoing provisions shall be inadequate and that, in addition to any other relief which may be available, GenVec shall be entitled to temporary and permanent injunctive relief without the necessity of proving actual damages.

5. This Agreement shall terminate upon the earlier to occur of the consummation of the Merger or the termination of the Reorganization Agreement.

Unless otherwise defined, capitalized terms used in this Agreement shall have the meanings ascribed to such terms in the Reorganization Agreement.

B-2

April 14, 2003

Page 3

IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above written.

Very truly yours,

By: S/ Jeffrey Steinberg

-----  
Name: Jeffrey Steinberg  
Title: Administrative Partner of  
HealthCare Partners II, L.P.  
The General Partner of HealthCare  
Ventures, II, L.P.

Accepted this 15th day  
of April, 2003

GENVEC, INC.

By: S/ Paul H. Fischer

-----  
Name: Paul H. Fischer  
Title: Chief Executive Officer

B-3

EXHIBIT C

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

April 14, 2003

GenVec, Inc.  
65 West Watkins Mill Road  
Gaithersburg, Maryland 20878

Ladies and Gentlemen:

The undersigned is the beneficial holder of shares of Diacrin, Inc. ("Diacrin") common stock, par value \$0.01 per share ("Diacrin Common Stock").

GenVec, Inc. ("GenVec") and Diacrin are considering the execution of an Agreement and Plan of Reorganization (the "Reorganization Agreement") providing for the merger of Diacrin with and into GenVec (the "Merger"). The execution of the Reorganization Agreement is subject, in the case of GenVec, to the execution and delivery of this letter agreement (this "Agreement"). In consideration of the substantial expenses that GenVec will incur in connection with the Merger and in order to induce GenVec to execute the Reorganization Agreement and to proceed to incur such expenses, the undersigned agrees and undertakes, in his capacity as a stockholder of Diacrin, as follows:

1. The undersigned will vote or cause to be voted for approval of the transactions contemplated by the Reorganization Agreement 897,757 of the shares of Diacrin Common Stock (the "Subject Shares") the undersigned is entitled to vote with respect thereto, subject, in the case of shares held in a fiduciary capacity, to the fiduciary, contractual or similar obligations of the undersigned.

2. The undersigned will not effect any transfer or other disposition (except by operation of law) of any of the Subject Shares until Diacrin's stockholders have voted to approve the transactions contemplated by the Reorganization Agreement or until the Reorganization Agreement has been terminated pursuant to its terms, except for any transfer mandated by law or court order. In the case of any transfer by operation of law or otherwise, this Agreement shall be binding upon and inure to the benefit of the transferee to the extent permitted by law. Any transfer or other disposition in violation of the terms of this paragraph 2 shall be null and void.

3. During the period beginning on the Effective Date and continuing to and including the date that is 120 days after the Effective Date, the undersigned will not, directly or indirectly (i) offer, sell, contract to sell or otherwise dispose of, any shares of GenVec Common Stock or securities convertible into or exercisable or exchangeable for shares of GenVec common stock or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part, the economic consequences of ownership of shares of GenVec Common Stock whether any such swap or other agreement is to be settled by delivery of shares of GenVec Common Stock, other securities, cash or otherwise.

C-1

April 14, 2003  
Page 2

4. The undersigned acknowledges and agrees that any remedy at law for breach of the foregoing provisions shall be inadequate and that, in addition to any other relief which may be available, GenVec shall be entitled to temporary and permanent injunctive relief without the necessity of proving actual damages.

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

5. This Agreement shall terminate upon the earlier to occur of the consummation of the Merger or the termination of the Reorganization Agreement.

Unless otherwise defined, capitalized terms used in this Agreement shall have the meanings ascribed to such terms in the Reorganization Agreement.

C-2

April 14, 2003  
Page 3

IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above written.

Very truly yours,

By: S/ Jeffrey Steinberg

-----  
Name: Jeffrey Steinberg  
Title: Administrative Partner of  
HealthCare Partners III, L.P.  
The General Partner of HealthCare  
Ventures, III, L.P.

Accepted this 15th day  
of April, 2003

GENVEC, INC.

By: /S Paul H. Fischer

-----  
Name: Paul H. Fischer  
Title: Chief Executive Officer

C-3

EXHIBIT D

April 14, 2003

GenVec, Inc.  
65 West Watkins Mill Road  
Gaithersburg, Maryland 20878

Ladies and Gentlemen:

The undersigned is the beneficial holder of shares of Diacrin, Inc. ("Diacrin") common stock, par value \$0.01 per share ("Diacrin Common Stock").

GenVec, Inc. ("GenVec") and Diacrin are considering the execution of an Agreement and Plan of Reorganization (the "Reorganization Agreement") providing



Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

for the merger of Diacrin with and into GenVec (the "Merger"). The execution of the Reorganization Agreement is subject, in the case of GenVec, to the execution and delivery of this letter agreement (this "Agreement"). In consideration of the substantial expenses that GenVec will incur in connection with the Merger and in order to induce GenVec to execute the Reorganization Agreement and to proceed to incur such expenses, the undersigned agrees and undertakes, in his capacity as a stockholder of Diacrin, as follows:

1. The undersigned will vote or cause to be voted for approval of the transactions contemplated by the Reorganization Agreement 263,677 of the shares of Diacrin Common Stock (the "Subject Shares") the undersigned is entitled to vote with respect thereto, subject, in the case of shares held in a fiduciary capacity, to the fiduciary, contractual or similar obligations of the undersigned.

2. The undersigned will not effect any transfer or other disposition (except by operation of law) of any of the Subject Shares until Diacrin's stockholders have voted to approve the transactions contemplated by the Reorganization Agreement or until the Reorganization Agreement has been terminated pursuant to its terms, except for any transfer mandated by law or court order. In the case of any transfer by operation of law or otherwise, this Agreement shall be binding upon and inure to the benefit of the transferee to the extent permitted by law. Any transfer or other disposition in violation of the terms of this paragraph 2 shall be null and void.

3. During the period beginning on the Effective Date and continuing to and including the date that is 120 days after the Effective Date, the undersigned will not, directly or indirectly (i) offer, sell, contract to sell or otherwise dispose of, any shares of GenVec Common Stock or securities convertible into or exercisable or exchangeable for shares of GenVec common stock or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part, the economic consequences of ownership of shares of GenVec Common Stock whether any such swap or other agreement is to be settled by delivery of shares of GenVec Common Stock, other securities, cash or otherwise.

D-1

April 14, 2003  
Page 2

4. The undersigned acknowledges and agrees that any remedy at law for breach of the foregoing provisions shall be inadequate and that, in addition to any other relief which may be available, GenVec shall be entitled to temporary and permanent injunctive relief without the necessity of proving actual damages.

5. This Agreement shall terminate upon the earlier to occur of the consummation of the Merger or the termination of the Reorganization Agreement.

Unless otherwise defined, capitalized terms used in this Agreement shall have the meanings ascribed to such terms in the Reorganization Agreement.

D-2

April 14, 2003  
Page 3

Edgar Filing: DIACRIN INC /DE/ - Form SC 13D/A

IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above written.

Very truly yours,

By: S/ Jeffrey Steinberg

-----  
Name: Jeffrey Steinberg  
Title: Administrative Partner of  
HealthCare Partners IV, L.P.  
The General Partner of  
HealthCare Ventures, IV, L.P.

Accepted this 15th day  
of April, 2003

GENVEC, INC.

By: /S Paul H. Fischer

-----  
Name: Paul H. Fischer  
Title: Chief Executive Officer

D-3